Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1994 Jun;69(6):1038–1042. doi: 10.1038/bjc.1994.204

Anti-tumour activity of low-toxicity lipopolysaccharide of Bordetella pertussis.

M Ohnishi 1, S Kimura 1, M Yamazaki 1, H Oshima 1, D I Mizuno 1, S Abe 1, H Yamaguchi 1
PMCID: PMC1969440  PMID: 8198967

Abstract

A lipopolysaccharide (BP-LPS) isolated from killed Bordetella pertussis (Tohama strain) was determined to have low toxicity based on the mortality and decrease in body weight of BP-LPS-injected mice. BP-LPS, administered intradermally or intraperitoneally, clearly inhibited the growth of an MM46 murine mammary carcinoma. When compared with a toxic Escherichia coli-derived LPS, BP-LPS displayed excellent anti-tumour activity against MH134 hepatoma and Meth A fibrosarcoma. As part of a combined chemotherapy/immunotherapy regimen, BP-LPS also seemed to prolong the lifespan of mice inoculated with Lewis lung carcinoma. BP-LPS thus appears to have valuable characteristics as an anti-tumour agent.

Full text

PDF
1038

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Abe S., Takahashi K., Tsubouchi J., Yamazaki M., Mizuno D. Combination therapy of murine tumors with lentinan, bacterial lipopolysaccharide and a Streptococcus preparation, OK432. Gan. 1983 Apr;74(2):273–278. [PubMed] [Google Scholar]
  2. Abe S., Takahashi K., Yamazaki M., Mizuno D. Complete regression of Lewis lung carcinoma by cyclophosphamide in combination with immunomodulators. Jpn J Cancer Res. 1985 Jul;76(7):626–630. [PubMed] [Google Scholar]
  3. Abe S., Yoshioka O., Masuko Y., Tsubouchi J., Kohno M., Nakajima H., Yamazaki M., Mizono D. Combination antitumor therapy with lentinan and bacterial lipopolysaccharide against murine tumors. Gan. 1982 Feb;73(1):91–96. [PubMed] [Google Scholar]
  4. Amano K., Ribi E., Cantrell J. L. Different structural requirements of endotoxic glycolipid for tumor regression and endotoxic activity. Biochem Biophys Res Commun. 1982 Jun 15;106(3):677–682. doi: 10.1016/0006-291x(82)91764-8. [DOI] [PubMed] [Google Scholar]
  5. Berendt M. J., North R. J., Kirstein D. P. The immunological basis of endotoxin-induced tumor regression. Requirement for T-cell-mediated immunity. J Exp Med. 1978 Dec 1;148(6):1550–1559. doi: 10.1084/jem.148.6.1550. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Galanos C., Lüderitz O., Rietschel E. T., Westphal O., Brade H., Brade L., Freudenberg M., Schade U., Imoto M., Yoshimura H. Synthetic and natural Escherichia coli free lipid A express identical endotoxic activities. Eur J Biochem. 1985 Apr 1;148(1):1–5. doi: 10.1111/j.1432-1033.1985.tb08798.x. [DOI] [PubMed] [Google Scholar]
  7. Gmeiner J., Lüderitz O., Westphal O. Biochemical studies on lipopolysaccharides of Salmonella R mutants. 6. Investigations on the structure of the lipid A component. Eur J Biochem. 1969 Jan;7(3):370–379. doi: 10.1111/j.1432-1033.1969.tb19618.x. [DOI] [PubMed] [Google Scholar]
  8. Kotani S., Takada H., Tsujimoto M., Ogawa T., Takahashi I., Ikeda T., Otsuka K., Shimauchi H., Kasai N., Mashimo J. Synthetic lipid A with endotoxic and related biological activities comparable to those of a natural lipid A from an Escherichia coli re-mutant. Infect Immun. 1985 Jul;49(1):225–237. doi: 10.1128/iai.49.1.225-237.1985. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Masuko Y., Nakajima H., Tsubouchi J., Yamazaki M., Mizuno D., Abe S. Changes of antitumor immunity of hosts with murine mammary tumors regressed by lentinan: potentiation of antitumor delayed hypersensitivity reaction. Gan. 1982 Oct;73(5):790–797. [PubMed] [Google Scholar]
  10. Minagawa H., Kakamu Y., Yoshida H., Tomita F., Oshima H., Mizuno D. Endogenous tumor necrosis factor induction with Bordetella pertussis vaccine as a triggering agent and its therapeutic effect on MM46 carcinoma-bearing mice. Jpn J Cancer Res. 1988 Mar;79(3):384–389. doi: 10.1111/j.1349-7006.1988.tb01602.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Minagawa H., Kobayashi H., Yoshida H., Teranishi M., Morikawa A., Abe S., Oshima H., Mizuno D. I. Intratumoral induction of tumour necrosis factor by systemic administration of Bordetella pertussis vaccine. Br J Cancer. 1990 Sep;62(3):372–375. doi: 10.1038/bjc.1990.300. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Mizuno D., Yoshioka O., Akamatu M., Kataoka T. Antitumor effect of intracutaneous injection of bacterial lipopolysaccharide. Cancer Res. 1968 Aug;28(8):1531–1537. [PubMed] [Google Scholar]
  13. Qureshi N., Takayama K., Ribi E. Purification and structural determination of nontoxic lipid A obtained from the lipopolysaccharide of Salmonella typhimurium. J Biol Chem. 1982 Oct 10;257(19):11808–11815. [PubMed] [Google Scholar]
  14. Ribi E. Beneficial modification of the endotoxin molecule. J Biol Response Mod. 1984;3(1):1–9. [PubMed] [Google Scholar]
  15. Rudbach J. A., Cantrell J. L., Ulrich J. T., Mitchell M. S. Immunotherapy with bacterial endotoxins. Adv Exp Med Biol. 1990;256:665–676. doi: 10.1007/978-1-4757-5140-6_61. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES